Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility

Valenzuela, María Teresa; Altuzarra, Rogelio H; Trucco, Olivia; Villegas, Rodrigo R; Inostroza, Jaime; Granata, Paulo S; Fleiderman, José V; Maggi, L

doi:10.1590/s1413-86702007000300005

Cited by 14 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…119,129,130 Interestingly, South African women infected with human immunodeficiency virus (HIV)were more likely to develop IPD with pediatric serotypes compared with HIV-infected men, likely because of women's closer proximity to small children. 131 Widespread pneumococcal vaccination may reduce risk of IPD in closed populations 68,132 and the community at large. 23,55 Infants < 6 months old may be relatively protected via passive transfer of maternal antibodies during breast-feeding.…”

Section: Risk Factors For Invasive Pneumococcal Diseasementioning

confidence: 99%

Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention

Lynch¹,

Zhanel²

2009

Semin Respir Crit Care Med

229

117

View full text Add to dashboard Cite

Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD) primarily affects young children, older adults (> 65 years of age), and individuals with comorbidities or impaired immune systems. Case fatality rates range from 10 to 30% in adults with IPD but are much lower (< 3%) in children. In this article, we describe the epidemiology of IPD, risk factors, and the influence of host- and organism-specific factors on outcomes. Most cases of IPD are caused by a limited number of serotypes that vary in infectivity and virulence. Vaccinating adults and high-risk patients with the pneumococcal polysaccharide vaccine reduces the incidence of IPD in populations at risk but does not affect nasopharyngeal colonization and has had limited benefit in the population at large. Use of the heptavalent pneumococcal conjugate vaccine (PCV7) in children in the United States since 2000 has resulted in a substantial decline of IPD in both children and adults (by herd immunity), but has facilitated the emergence of serotypes not encompassed in the PCV7 vaccine. Recent reports of "replacement" serotypes that have heightened virulence are worrisome. In this chapter, we discuss the role of vaccines (both polysaccharide and conjugate) and other preventive strategies to limit this important and potentially lethal disease.

show abstract

Section: Risk Factors For Invasive Pneumococcal Diseasementioning

confidence: 99%

Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention

Lynch¹,

Zhanel²

2009

Semin Respir Crit Care Med

229

117

View full text Add to dashboard Cite

show abstract

“…In this group, pneumonia is regarded a special category due to advanced age, numerous co-morbidities and non-specific, but often severe disease course, which all contribute to a high (30%) mortality rate (2). One of the main pathogens causing pneumonia in the group of elderly is S. pneumoniae ( Streptococcus pneumoniae ; 4-7). …”

Section: Introductionmentioning

confidence: 99%

Nasopharyngeal carriage of Streptococcus pneumoniae and serotypes indentified among nursing home residents in comparison to the elderly and patients younger than 65 years living in domestic environment

Kolšek-Šušteršič

Krasnič

Mioč

et al. 2017

Slovenian Journal of Public Health

View full text Add to dashboard Cite

IntroductionIn Slovenia, there is little data available on pneumococcal vaccination rates and no data on asymptomatic NPCR and serotypes in the population of nursing home residents in comparison to the elderly living in domestic environment, therefore the goal was to gain these data.MethodsA cross sectional epidemiological study was performed. Nasopharyngeal swabs from 151 nursing home residents, 150 elderly living in domestic environment, and 38 adults less than 65 years old were collected twice (in two consecutive years). The swabs were analysed for pneumococcal identification and serotyping. Patient data were collected from medical files and medical history.ResultsNo statistically significant differences in NPCR were seen between compared groups in two consecutive years. An average NPCR in two consecutive years in nursing home residents was 1.45%, in the elderly living in domestic environment 0.85%, and in adults less than 65 years old 7.05%. Serotypes identified among nursing home residents were 6B and 9N, among the group of elderly living in domestic environment, 6A and among adults less than 65 years old, 35F, 18C and 3. Pneumococcal vaccination rates were low (3.3% in nursing home residents, 6% in the elderly from domestic environment and 0% in the group of adults less than 65 years old).ConclusionsOur data suggests that NPCR and the proportion of people vaccinated with pneumococcal vaccine among the elderly are low. We identified different serotypes in all groups, only one person was a chronic carrier (serotype 35F).

show abstract

“…En un estudio chileno se pudo demostrar la permanencia de los niveles de anticuerpos al cabo de dos años de seguimiento en adultos mayores de 60 años de edad 10 . La relación entre concentración sérica de anticuerpos y protección otorgada por la vacuna polisacárida no ha sido bien establecida 3,27 .…”

Section: Inmunogenicidadunclassified

Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología acerca de la eficacia de la vacuna anti-neumocóccica 23 valente en el adulto mayor: Febrero 2010

Abarca

et al. 2010

Rev. chil. infectol.

View full text Add to dashboard Cite

The article summarizes the scientific evidence related with protection conferred by the 23 valent polysacchardie vaccine against invasive pneumococcal disease, non bacteriemic pneumococcal pneumonia, and probable pneumococal pneumonia in the elderly. Elder patients with and without risk factors are considered. The impact of herd immunitty conferred by vaccination of children with conjugated pneumococcal vaccine in reduction of penumonia in adults is discussed. Based on this analysis, the Advisory Committee on Immunizations of the Chilean Infectious Disease Society makes recommendations on the most efficient vaccine strategy for reduction of pneumococcal pneumonia in the elderly. Key words: 23 valent polysaccharide pneumococcal vaccine Streptococcus pneumoniae, pneumococcal invasive disease, pneumonia, elderly people. Palabras clave: Vacuna anti-neumocóccica polisacárida 23-valente Streptococcus pneumoniae, enfermedad neumocóccica invasora, neumonías, adulto mayor.

show abstract

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility

Cited by 14 publications

References 19 publications

Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention

Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention

Nasopharyngeal carriage of Streptococcus pneumoniae and serotypes indentified among nursing home residents in comparison to the elderly and patients younger than 65 years living in domestic environment

Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología acerca de la eficacia de la vacuna anti-neumocóccica 23 valente en el adulto mayor: Febrero 2010

Contact Info

Product

Resources

About